Profile | GDS2987 / GI_22212924-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 7.3 | 17 |
GSM215344 | HMVEC_atorvastatin_rep2 | 1.3 | 3 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 19 | 35 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 10.3 | 17 |
GSM215297 | PASMC_vehicle_rep1 | 3.1 | 5 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 34.1 | 48 |
GSM215311 | PASMC_atorvastatin_rep1 | 1.2 | 2 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 13.5 | 20 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 8.1 | 14 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 2.5 | 5 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 2.4 | 4 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 3 | 6 |
GSM215329 | PASMC_SLx2119_rep3 | 19.3 | 35 |
GSM215330 | Fibroblasts_vehicle_rep1 | 17.3 | 38 |
GSM215331 | Fibroblasts_vehicle_rep2 | 14.5 | 38 |
GSM215332 | Fibroblasts_vehicle_rep3 | 4.4 | 15 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 10.1 | 33 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 9.3 | 26 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 10.3 | 30 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 |